SEC Form 4 · accession 0001209191-19-005667
GYRE THERAPEUTICS, INC. · GYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Fletcher Payne
Officer — Chief Financial Officer
Period of report
Jan 24, 2019
Accepted (ET)
Jan 28, 2019 · 6:56 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001124105
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $7.97 | Jan 24, 2019 | A | 38,000 | A | — | Jan 24, 2029 | Common Stock | 38,000 | 38,000 | D |
Explanation of responses
- F1Award vests over a four (4) year period on each monthly anniversary commencing January 24, 2019.